Tilray Brands Inc
Tilray Brands Inc has a liquidity position that is currently medium, with a current ratio of 2.46 and a negative free cash flow of -$2.08 billion. The company's cash and equivalents stand at $221.67 million, but this is offset by long-term debt of $302.72 million, resulting in a net cash position that is negative. The debt-to-equity ratio is 0.2, indicating a relatively low level of leverage compared to the industry median. Profitability metrics for Tilray are significantly below industry norms, with a return on equity of -1.4468 and a return on assets of -1.0542. The company reported a net loss of $2.19 billion for the period, with operating income also in the red at -$2.28 billion. These figures suggest that the company is not currently generating returns that meet the expectations of its equity and asset base. Tilray's revenue is concentrated in a few key markets, with the United States and Canada being the primary geographic contributors. The company's exposure to these markets is significant, and any regulatory or economic shifts in these regions could have a material impact on its financial performance. The company's segmental breakdown is not fully disclosed, but the focus on cannabis-based products for medical and adult-use markets is a core part of its business model. Looking ahead, Tilray's growth trajectory is uncertain, with the company reporting a revenue of $821.31 million for the period. Analysts have provided a range of price targets, from $6.50 to $24.00, with a mean of $11.04 and a median of $9.50. The mean recommendation is 2.64, indicating a mixed outlook with a slight bias toward caution. The company's ability to achieve positive growth will depend on its capacity to improve profitability and manage its liquidity challenges. The risk assessment for Tilray highlights a medium liquidity risk and a low dilution risk. The company's negative free cash flow and negative net cash position are key liquidity concerns. While the dilution risk is currently low, the company's financial performance and capital structure could change this outlook if it needs to raise additional capital. The risk assessment also notes that the company's net cash is negative after subtracting total debt, which could affect its ability to fund operations and growth initiatives. Recent events and filings indicate that Tilray is navigating a challenging regulatory and market environment. The company's financial performance has been impacted by the highly competitive cannabis industry and the regulatory uncertainties in key markets. Management has been focused on cost optimization and strategic realignment to improve the company's financial position. The company's recent earnings call transcripts and investor relations communications reflect a commitment to long-term value creation despite current financial challenges.
Business. Tilray Brands Inc is a global cannabis and wellness company that develops, produces, and distributes cannabis-based products for medical, adult-use, and wellness markets.
Classification. Tilray is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a confidence level of 0.92.
- Tilray Brands Inc is experiencing significant financial losses, with a net loss of $2.19 billion and a negative return on equity of -1.4468.
- The company's liquidity position is medium, with a current ratio of 2.46 and a negative free cash flow of -$2.08 billion.
- Tilray's profitability is below industry norms, with a return on assets of -1.0542 and a debt-to-equity ratio of 0.2.
- The company's revenue is concentrated in the United States and Canada, making it vulnerable to regulatory and economic changes in these markets.
- Analysts have provided a mixed outlook, with a mean price target of $11.04 and a mean recommendation of 2.64.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.